TABLE 3

Allele frequencies of CAPN10 SNPs in Finland

A. MarkerAlleleBotnia I
Botnia II
Pooled
Type 2 diabetesControl subjectsPType 2 diabetesControl subjectsPType 2 diabetesControl subjectsP
SNP-441 (T)293 (78.3)288 (75.0)0.28327 (80.5)173 (81.6)0.75620 (79.5)461 (77.3)0.34
2 (C)81 (21.7)96 (25.0)79 (19.5)39 (18.4)160 (20.5)135 (22.7)
SNP-431 (G)294 (76.6)259 (67.4)0.0049301 (74.5)153 (72.9)0.66595 (75.5)412 (69.4)0.011
2 (A)90 (23.4)125 (32.6)103 (25.5)57 (27.1)193 (24.5)182 (30.6)
SNP-192 (ins)217 (56.5)236 (61.5)0.16229 (56.4)112 (52.8)0.40446 (56.5)348 (58.4)0.47
1 (del)167 (43.5)148 (38.5)177 (43.6)100 (47.2)344 (43.5)248 (41.6)
SNP-631 (C)356 (92.7)369 (96.6)0.017346 (85.2)183 (86.3)0.71702 (88.9)552 (92.9)0.010
2 (T)28 (7.3)13 (3.4)60 (14.8)29 (13.7)88 (11.1)42 (7.1)
  • Data are n (%). All SNPs were genotyped in 395 patients with type 2 diabetes and 298 control subjects. In all, 0.3% of the genotypes could not be provided despite repeated genotyping. Allele frequencies of SNP-43 and -44 did not significantly differ between Botnia I and II samples, whereas SNP-19 allele 1 was more common among control subjects from Botnia II compared with control subjects from Botnia I (47.2 vs. 38.5%; P = 0.041). The SNP-63 allele 2 was substantially more common among both type 2 diabetic patients and control subjects in Botnia II than in Botnia I (14.8 vs 7.3, [P = 0.00080] and 13.7 vs. 3.4% [P = 0.000013] for type 2 diabetic patients and control subjects in Botnia II and I, respectively). All genotype frequencies were in Hardy-Weinberg equilibrium, and those of SNP-43 and -63 differed significantly between type 2 diabetic patients and healthy control subjects (SNP-43: 57.6, 35.8, and 6.6 vs. 48.2, 42.4, and 9.4%; P = 0.039; SNP-63: 79.8, 18.2, and 2.0 vs. 87.2, 11.5, and 1.4%, P = 0.036 for genotypes 11, 12, and 22, respectively).